News of the company Xantos Biomedicine

Article 1 to 5 out of 5 concerning Xantos Biomedicine AG

Xantos Biomedicine AG has approved funding from the Bavarian Ministry of Economy (12/01/2005)
Xantos Biomedicine AG announced that it has been awarded a grant from the Bavarian Ministry of Economic Affairs, Infrastructure, Transport and Technology (=BayStMWIVT) for the expansion of its technology platform. The overall aim of the project, ...

more information
�
Xantos Biomedicine and QIAGEN AnnounceCo-Marketing Agreement for RNAi Library with High-Content Cellular Screening System (08/10/2005)
Xantos Biomedicine AG and QIAGEN N.V. announced their partnership for co-marketing QIAGEN's proprietary TOM-amidite chemistry based genome-wide RNAi products with Xantos' automated cell-based screening platform, XantoScreen(TM). By combining the ...

more information
�
Xantos Biomedicine AG and Cryptome Pharmaceuticals Ltd collaborate to validate cancer lead (06/21/2005)
Xantos Biomedicine AG announced that it has signed a collaboration agreement with Cryptome Pharmaceuticals Ltd, Melbourne, Australia. Xantos has used XantoScreen(TM) technology to discover novel proteins that mediate proliferation of vascular ...

more information
�
Xantos Biomedicine AG, NascaCell and PSF biotech collaborate on cancer drug discovery project (04/15/2005)
Xantos Biomedicine AG announced a collaboration with NascaCell IP GmbH and PSF biotech AG. The consortium is set to identify and develop new drugs for the inhibition of tumour angiogenesis, a process by which the growth of blood cells from ...

more information
�
Xantos Biomedicine AG Receives Funding From Sixth EU Framework Program For Angiotargeting Project (02/25/2005)
Xantos Biomedicine AG announced that it has been awarded a grant from the European Commission Sixth Framework program for the discovery and validation of new targets and pathways involved in tumor induced blood vessel formation. The overall aim of ...

more information
�

Current NewsRSS

Current News RSS